Journals / Koşuyolu Heart Journal / 2010 / Cilt: 13 - Sayı: 2

Association Between Apolipoprotein-B100 and Apolipoprotein-A1 in Patients with Coronary Slow Flow

Koroner Yavafl Ak›m Hastalar›nda Apolipoprotein-B100 ve Apolipoprotein-A1 Aras›ndaki ‹liflki

Pages
11–15
Publication Date
2009-02-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Although lower levels of plasma Apo-A1 and higher levels of Apo-B and the ratio of Apo-B to Apo-A1 are related with CAD, there is no relationship between these apolipoproteins and CSFP.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Although several hypotheses have been suggested, the underlying mechanism of coronary slow flow phenomenon (CSFP) has not been well established yet.
📊
Key Findings & Data:The aim of this study was to determine the roles of plasma apolipoprotein-B100 (Apo-B) and apolipoprotein-A1 (Apo-A1) in CSFP which have an atherogenic effect and anti-atherogenic effects respectively.
💡
Conclusion & Impact:Conclusion: Although lower levels of plasma Apo-A1 and higher levels of Apo-B and the ratio of Apo-B to Apo-A1 are related with CAD, there is no relationship between these apolipoproteins and CSFP.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Koroner yavafl ak›m fenomeni · Apolipoproteinler · Aterojenik ve anti-aterojenik etki

Abstract

Objective: Although several hypotheses have been suggested, the underlying mechanism of coronary slow flow phenomenon (CSFP) has not been well established yet. The aim of this study was to determine the roles of plasma apolipoprotein-B100 (Apo-B) and apolipoprotein-A1 (Apo-A1) in CSFP which have an atherogenic effect and anti-atherogenic effects respectively. Methods: The study consisted of 31 patients with CSFP (group 1), 28 normal subjects as control group (group 2) and 30 patients with coronary artery disease (CAD) (group 3) detected by coronary angiography. CSFP was diagnosed by the TIMI frame count method. Blood Apo-B, Apo-A1, Apo-B/Apo-A1 ratio, and demographic parameters were compared between the groups. Results: The Apo-B values were 93±25 mg/dL, 90±26 mg/dL, and 106±27 mg/dL in groups 1, 2 and 3, respectively (p=0.048 between group 1 and 3, p=0.041 between group 2 and 3, p= NS between group 1 and 2). The Apo-A1values were 127±14 mg/dL, 125±21 mg/dL and 106±27 mg/dL in groups 1, 2 and 3 respectively (p=0.028 between group 1 and 3, p=0.021 between group 2 and 3, p= NS between group 1 and 2). The apo- B/apo-A1 ratio were 0.73±0.18, 0.69±0.23 and 0.98±0.20 in groups 1, 2 and 3 respectively (p=0.017 between group 1 and 3, p=0.010 between group 2 and 3, p= NS between group 1 and 2). Conclusion: Although lower levels of plasma Apo-A1 and higher levels of Apo-B and the ratio of Apo-B to Apo-A1 are related with CAD, there is no relationship between these apolipoproteins and CSFP.

Özet

Amaç: Koroner yavafl ak›m fenomenin (KYAF) altta yatan mekanizmas› henüz tam olarak tan›mlanmam›fl olmas› na ra¤men çeflitli hipotezler ileri sürülmüfltür. Bu çal›flmam›z da s›ras›yla aterojenik ve anti-aterojenik etki gösteren plazma apolipoprotein-B100 (Apo-B) ve apolipoprotein-A1'in (Apo-A1) KYAF'deki rolünü araflt›rd›k. Yöntemler: Çal›flmaya koroner anjiografik olarak KYAF'si olan 31 hasta (grup 1) ile normal kiflilerden oluflan 28 kontrol grubu (grup 2) ve koroner arter hastal›¤› olan 30 hasta (grup 3) al›nd›. KYAF tan›s› TIMI kare say›s› yöntemiyle kondu. Gruplar›n plazma Apo-B, Apo-A1, Apo-B/Apo-A1 oran› ve demografik özellikleri karfl›laflt›r›ld›. Bulgular: Grup 1, 2 ve 3'deki ortalama Apo-B de¤erlerini s›ras›yla 93±25 mg/dL, 90±26 mg/dL, 106±27 mg/dL olarak saptad›k (grup 1 ile 3 aras›ndaki p=0.048, grup 2 ile 3 aras›ndaki p=0.041, grup 1 ile 2 aras›ndaki p= AD). Grup 1, 2 ve 3'deki ortalama Apo-A1 de¤erlerini s›ras›yla 127±14 mg/dL, 125±21 mg/dL, 106±27 mg/dL olarak saptad›k (grup 1 ile 3 aras›ndaki p=0.028, grup 2 ile 3 aras›ndaki p=0.021, grup 1 ile 2 aras›ndaki p= AD). Grup 1, 2 ve 3'deki Apo-B/Apo-A1 oran›n› ise s›ras›yla 0.73±0.18, 0.69±0.23 ve 0.98±0.20 olarak saptad›k (grup1 ile 3 aras›ndaki p=0.017, grup 2 ile 3 aras›ndaki p=0.010, grup 1 ile 2 aras›ndaki p= AD). Sonuç: Koroner arter hastal›¤› düflük plazma Apo-A1 düzeyi ile yüksek plazma Apo-B düzeyi ve Apo-B/Apo- A1 oran› ile iliflkilendirilmifl olmas›na ra¤men apolipoproteinler ile KYAF aras›nda bu iliflki bulunmam›flt›r.

🔖

Cite This Article

Kargin, R., Emiroglu, Y., Pala, S., Akcakoyun, M., Aung, S. M., Candan, Ö., Hatipo¤lu, S., Özdemir, N. (2009). Association Between Apolipoprotein-B100 and Apolipoprotein-A1 in Patients with Coronary Slow Flow. Koşuyolu Heart Journal, Cilt: 13 - Sayı: 2, 11–15. https://ajindex.com/articles/64127

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Mangieri E, Macchiarelli G, Ciavolella M, Barillà F, Avella A, Martinotti A, et al. Slow coronary flow: clinical and histopatho- logical features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn 1996;37:375–81.
  2. Mosseri M, Yarom R, Gotsman MS, Hasin Y. Histologic evi- dence for small vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation 1986;74:964–72.
  3. Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arte- ries a new angiographic finding. Am Heart J 1972;84:66–71.
  4. Rim SJ, Leong-Poi H, Lindner JR, Wei K, Fisher NG, Kaul S. Decrease in coronary blood flow reserve during hyperlipidemi- a is secondary to an increase in blood viscosity. Circulation 2001;104:2704–9.
  5. Pekdemir H, Polat G, Cin VG, Camsari A, Cicek D, Akkus MN, et al. Elevated plasma endothelin-1 levels in coronary si- nus during rapid right atrial pacing in patients with slow coro- nary flow. Int J Cardiol 2004;97:35–41.
  6. Camsari A, Pekdemir H, Cicek D, Polat G, Akkus MN, Döven O, et al. Endothelin-1 and nitric oxide concentrations and the- ir response to exercise in patients with slow coronary flow. Circ J 2003;67:1022–8.
  7. Sezgin N, Barutcu I, Sezgin AT, Gullu H, Turkmen M, Esen AM, et al. Plasma nitric oxide level and its role in slow coronary phenomenon. Int Heart J 2005;46:373–82.
  8. Jian-Jun Li, Bo Xu, Zi-Cheng Li, Jie Qian, Bing-Qi Wei. Is slow coronary flow associated with inflammation? Medical Hypotheses 2006;66:504–8
  9. Lanza GA, Andreotti F, Sestio A, Sciahbasi A, Crea F, Mase- ri A. Platelet aggregability in cardiac syndrome X. Eur Heart J 2001;22:1924–30.
  10. Gokce M, Kaplan S, Tekelioglu Y, Erdoğan T, Küçükosma- noğlu M. Platelet function disorder in patients with coronary slow flow. Clin Cardiol 2005;28:145–8.
  11. Evrengul H, Tanriverdi H, Enli Y, Kuru O, Seleci D, Bastemir M, et al. Interaction of Plasma Homocysteine and Thyroid Hor- mone Concentrations in the Pathogenesis of the Slow Coro- nary Flow Phenomenon. Cardiology 2007;108:186–192
  12. Walldius G, Junger I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy– a review of the evidence. J Int Med 2006;259:493–519
  13. Jadhav UM, Kadam NN. Apolipoproteins: Correlation with Carotid Intima-Media Thickness and Coronary Artery Disease. J Assoc Physicians India. 2004;52:370-75.
  14. Schiller NB, Shah PM, Crawford M, DeMaria A, Devere- ux R, Feigenb